Viatris VTRS
NASDAQ VTRS
$16.50 -0.11 (-0.66%)
As of: Sep 9, 2026 · 3:59 PM EDT

Viatris (VTRS) Cash from Investing Activities (2019 - 2026)

Viatris (VTRS) posted Cash from Investing Activities of -$51.6 million for Q2 2026, down 118.6% on a QoQ basis from $277.4 million in Q1 2026, and up 1.71% year-over-year from -$50.7 million in Q2 2025.

Analysis

Viatris (VTRS) Cash from Investing Activities (2019 - 2026) Analysis & Trends

Viatris has reported Cash from Investing Activities for 8 years, with the latest figure at -$51.6 million in Q2 2026.

  • On a quarterly basis, Cash from Investing Activities rose 1.71% year-over-year to -$51.6 million in Q2 2026; TTM through Jun 2026 was -$84.3 million, a 105.77% decrease from a year earlier, with the FY2025 full-year figure at -$427.7 million, down 123.75% from the prior year.
  • Cash from Investing Activities was -$51.6 million for Q2 2026 at Viatris, down from $277.4 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $1.7 billion in Q3 2024, with the low at -$749.5 million in Q1 2023.
  • Average Cash from Investing Activities over 5 years is $122.7 million, with a median of -$66.0 million recorded in 2025.
  • The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities plunged 1020.33% in 2023, then jumped 3283.79% in 2024.
  • Over 5 years, Cash from Investing Activities stood at $1.7 billion in 2022, then plunged by 98.46% to $26.7 million in 2023, then slumped by 731.84% to -$168.7 million in 2024, then retreated by 25.19% to -$211.2 million in 2025, then jumped by 75.57% to -$51.6 million in 2026.
  • The last three Cash from Investing Activities figures came in at -$51.6 million (Q2 2026), $277.4 million (Q1 2026), and -$211.2 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Teva Pharmaceutical Industries 42.84 Bn 39.19 Bn 2.15 Bn -491.00 Mn
2 Viatris 19.13 Bn 18.24 Bn 1.46 Bn -51.60 Mn
3 Dr Reddys Laboratories 9.91 Bn 9.74 Bn 396.53 Mn 40.52 Mn
4 Amneal Pharmaceuticals 5.51 Bn 5.38 Bn 334.51 Mn -122.74 Mn
5 Bausch Health Companies 2.30 Bn 464.50 Mn 2.10 Bn -93.00 Mn
6 Alvotech 1.50 Bn 1.36 Bn 2.56 Mn -44.77 Mn
7 Ani Pharmaceuticals 1.49 Bn 1.13 Bn 165.89 Mn -3.05 Mn
8 Amphastar Pharmaceuticals 1.00 Bn 714.13 Mn 93.47 Mn 44.87 Mn
9 Fennec Pharmaceuticals 402.10 Mn 360.85 Mn 17.15 Mn -
10 RedHill Biopharma 178.35 Mn 178.35 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -51.60 Mn
Mar 31, 2026 277.40 Mn
Dec 31, 2025 -211.20 Mn
Sep 30, 2025 -98.90 Mn
Jun 30, 2025 -52.50 Mn
Mar 31, 2025 -65.10 Mn
Dec 31, 2024 -168.70 Mn
Sep 30, 2024 1.75 Bn
Jun 30, 2024 375.80 Mn
Mar 31, 2024 -154.30 Mn
Dec 31, 2023 26.70 Mn
Sep 30, 2023 -54.90 Mn
Jun 30, 2023 -86.80 Mn
Mar 31, 2023 -749.50 Mn
Dec 31, 2022 1.74 Bn
Sep 30, 2022 -115.00 Mn
Jun 30, 2022 -82.10 Mn
Mar 31, 2022 -66.90 Mn
Dec 31, 2021 -219.10 Mn
Sep 30, 2021 -118.20 Mn